News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Initial trial data is expected in the second half of 2026.
The company is currently raising $8.5 million to support further development of its diagnostic and prognostic tools.
Vasowatch received $150K from Ben Franklin Technology Partners.
Linnaeus will use these funds to further develop LNS880.
PCI hosted its annual Innovation @ Penn program at Wharton San Francisco.
The dedicated venture capital fund will invest in early-stage life science companies spun out of Penn.
Ten teams completed the program, and 26 individuals received valuable training in entrepreneurship.
The article discusses how nearly all significant modern medicines originated from taxpayer-funded university research.
The newly expanded 53,000-square-foot biotech incubator, the Philadelphia ATxCC aims to provide emerging startups and biopharma organizations with resources and tech.
The facility, which will support six to eight biotech startups, is set to open next year.